About

The Company

Omniose was founded in 2017 based on the pioneering glycoconjugation discoveries of our scientific founders Mario Feldman and Christian Harding through a scientific collaboration that characterized a new class of conjugating enzymes.  The research operations were established at BioGenerator Labs in St. Louis and the company was previously known as VaxNewMo.  Omniose has been awarded $4.6 million in grants from the US NIAID for use of our platform technology to develop vaccines against Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.

Omniose announced an expansion of the team in April 2022 with the addition of Timothy Cooke as CEO and Roman Fleck as Chairperson.  Both of these highly experienced executives will be based in the Boston area. The company also announced the formation of a Scientific Advisory Board with co-founder Mario Feldman, Steven Projan, who brings deep industry experience in infectious disease drug and vaccine development, and Viliam Pavliak, adding critical expertise in glycoconjugate vaccine CMC development.

Meet our Leadership Team

Timothy Cooke, Ph.D., M.B.A.
Chief Executive Officer
Christian Harding, Ph.D.
Chief Scientific Officer
& Co-Founder
Roman Fleck, Ph.D., M.B.A.
Chairperson
Mario Feldman, Ph.D.
Co-Founder &
Scientific Advisory Board Member
Christine Szymanski, Ph.D.
Co-Founder
Viliam Pavliak, Ph.D.
Scientific Advisory Board Member
Steven Projan, Ph.D.
Scientific Advisory Board Member